Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1608768 | 0.90 | CREBBP (0.44) | CNR2CNR1CREBBPBRD4MAPT | |
| SCHEMBL14099544 | 0.89 | CNR1 (0.43) | CNR2CNR1CREBBPBRD4 | |
| SCHEMBL13622688 | 0.83 | POLB (0.46) | CREBBPBRD4MAPTCYP1A2CYP2C19 | |
| SCHEMBL13622872 | 0.82 | CREBBP (0.42) | CREBBPBRD4MAPTCYP1A2CYP2C19 | |
| SCHEMBL1609124 | 0.80 | PTGER4 (0.48) | CREBBPBRD4MAPTCYP1A2CYP2C19 | |
| SCHEMBL14116543 | 0.78 | HTT (0.44) | CREBBPBRD4MAPTMEN1KMT2A | |
| SCHEMBL1609171 | 0.77 | HTT (0.58) | MAPTMEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL3995887 | 0.74 | CREBBP (0.43) | CNR2CNR1CREBBPMAPTCYP1A2 | |
| SCHEMBL5264091 | 0.73 | CREBBP (0.58) | CREBBPBRD4MEN1KMT2A | |
| SCHEMBL4966160 | 0.72 | KDM4E (0.53) | MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086853-A1 | Therapeutic Compounds | BROWN WILLIAM | 2011-04-14 | — | — | US | disclosed |
| US-20110086853-A1 | Therapeutic Compounds | BROWN WILLIAM | 2011-04-14 | — | — | US | disclosed |
| US-20110086853-A1 | Therapeutic Compounds | BROWN WILLIAM | 2011-04-14 | — | — | US | disclosed |
| US-7615642-B2 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2009-11-10 | — | — | US | disclosed |
| US-7615642-B2 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2009-11-10 | — | — | US | disclosed |
| US-7615642-B2 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2009-11-10 | — | — | US | disclosed |
| EP-2010526-A1 | BENZIMIDAZOLE 5-SULFONAMIDE DERIVATIVES AS CANNABINOID 1 (CB1) RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120101-A1 | BENZIMIDAZOLE 5-SULFONAMIDE DERIVATIVES AS CANNABINOID 1 (CB1) RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120101-A1 | BENZIMIDAZOLE 5-SULFONAMIDE DERIVATIVES AS CANNABINOID 1 (CB1) RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
| US-20070244092-A1 | N-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrrole-3-carboxamide; for pain management | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244092-A1 | N-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrrole-3-carboxamide; for pain management | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244092-A1 | N-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrrole-3-carboxamide; for pain management | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086853-A1 | Therapeutic Compounds | OPRL1, F12, F3 | CNR2 187/4885CNR1 35/4885CREBBP 1246/4885 |
| US-20070244092-A1 | N-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrrole-3-carboxamide; for pain management | OPRM1, OPRL1, OPRK1 | CNR2 13/4885CNR1 5/4885CREBBP 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.